A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.

Also called NCT03951805

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 205 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03951805
  • EudraCT 2018-003406-11
Other papers using this trial's data
  • A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100 Diabetes care, 2021-07 DOI, PubMed 33875484, PMC8323172 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Croatia, Germany, Hungary, Poland, Slovakia, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03951805. Randomized; no masking; primary purpose treatment. Start 2019-05-09 (actual); primary completion 2019-12-12 (actual). Results posted on 2021-01-08.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Insulin icodec
Intervention (Drug)
Insulin Glargine
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct03951805
Content hash
64292bf0e2864a1b356d4d8ffe0be3853a60369386969c4e9419ac1253c6fbe2